{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:38:51Z","timestamp":1790156331119,"version":"4.0.1"},"reference-count":143,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T00:00:00Z","timestamp":1515024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Bone is one of the most preferential target site for cancer metastases, particularly for prostate, breast, kidney, lung and thyroid primary tumours. Indeed, numerous chemical signals and growth factors produced by the bone microenvironment constitute factors promoting cancer cell invasion and aggression. After reviewing the different theories proposed to provide mechanism for metastatic progression, we report on the gene expression profile of bone-seeking cancer cells. We also discuss the cross-talk between the bone microenvironment and invading cells, which impacts on the tumour actions on surrounding bone tissue. Lastly, we detail therapies for bone metastases. Due to poor prognosis for patients, the strategies mainly aim at reducing the impact of skeletal-related events on patients\u2019 quality of life. However, recent advances have led to a better understanding of molecular mechanisms underlying bone metastases progression, and therefore of novel therapeutic targets.<\/jats:p>","DOI":"10.3390\/ijms19010148","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T11:52:47Z","timestamp":1515066767000},"page":"148","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets"],"prefix":"10.3390","volume":"19","author":[{"given":"Annie","family":"Schmid-Alliana","sequence":"first","affiliation":[{"name":"Centre National de la Recherche Scientifique (CNRS), Universit\u00e9 C\u00f4te d\u2019Azur, Inserm, iBV, 06108 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidy","family":"Schmid-Antomarchi","sequence":"additional","affiliation":[{"name":"Centre National de la Recherche Scientifique (CNRS), Universit\u00e9 C\u00f4te d\u2019Azur, Inserm, iBV, 06108 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Al-Sahlanee","sequence":"additional","affiliation":[{"name":"Centre National de la Recherche Scientifique (CNRS), Universit\u00e9 C\u00f4te d\u2019Azur, Inserm, iBV, 06108 Nice, France"},{"name":"College of Sciences, Biotechnology Department, University of Bagdad, Bagdad, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lagadec","sequence":"additional","affiliation":[{"name":"Centre National de la Recherche Scientifique (CNRS), Universit\u00e9 C\u00f4te d\u2019Azur, Inserm, iBV, 06108 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Scimeca","sequence":"additional","affiliation":[{"name":"Centre National de la Recherche Scientifique (CNRS), Universit\u00e9 C\u00f4te d\u2019Azur, Inserm, iBV, 06108 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Verron","sequence":"additional","affiliation":[{"name":"Regenerative Medicine and Skeleton. RMeS-Lab, INSERM UMR 1229, University of Nantes, 44000 Nantes, France"},{"name":"Chimie et Interdisciplinarit\u00e9, Synth\u00e8se, Analyse, Mod\u00e9lisation (CEISAM), UMR CNRS 6230, University of Nantes, 44300 Nantes, France"},{"name":"Faculty of Pharmaceutical Sciences, University of Nantes, 44000 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,1,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.semnuclmed.2014.07.004","article-title":"Evaluation of osseous metastasis in bone scintigraphy","volume":"45","author":"Davila","year":"2015","journal-title":"Semin. Nucl. Med."},{"key":"ref_2","first-page":"F77","article-title":"Molecular aspects of prostate cancer: Recent data from the literature","volume":"94","author":"Camparo","year":"2007","journal-title":"Bull. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO.2004.08.181","article-title":"Bone imaging in metastatic breast cancer","volume":"22","author":"Hamaoka","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_4","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast. 1889","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metastasis Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.euus.2005.09.006","article-title":"Molecular and Biological Mechanisms of Bone Metastasis","volume":"3","author":"Cecchini","year":"2005","journal-title":"EAU Update Ser."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.canlet.2008.05.044","article-title":"Osteotropic cancers: From primary tumor to bone","volume":"273","author":"Buijs","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bbrc.2004.11.070","article-title":"Crosstalk between cancer cells and bone microenvironment in bone metastasis","volume":"328","author":"Yoneda","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ata, R., and Antonescu, C.N. (2017). Integrins and Cell Metabolism: An Intimate Relationship Impacting Cancer. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18010189"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"H1055","DOI":"10.1152\/ajpheart.00042.2016","article-title":"When the endothelium scores an own goal: Endothelial cells actively augment metastatic extravasation through endothelial-mesenchymal transition","volume":"310","author":"Gasparics","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/nature03703","article-title":"In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment","volume":"435","author":"Sipkins","year":"2005","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0960-7404(99)00011-0","article-title":"Bone metastasis in breast cancer: The role of parathyroid hormone related protein","volume":"8","author":"Iddon","year":"1999","journal-title":"Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrc2627","article-title":"Parallel progression of primary tumours and metastases","volume":"9","author":"Klein","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_13","first-page":"1","article-title":"Foulds\u2019 dangerous idea revisited: The multistep development of tumors 40 years later","volume":"72","author":"Klein","year":"1998","journal-title":"Adv. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","article-title":"A genetic model for colorectal tumorigenesis","volume":"61","author":"Fearon","year":"1990","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/255197a0","article-title":"Mutation selection and the natural history of cancer","volume":"255","author":"Cairns","year":"1975","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1078-0432.CCR-05-1029","article-title":"The clinical value of somatic TP53 gene mutations in 1794 patients with breast cancer","volume":"12","author":"Olivier","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.cell.2008.04.045","article-title":"Systemic endocrine instigation of indolent tumor growth requires osteopontin","volume":"133","author":"McAllister","year":"2008","journal-title":"Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bjc.1984.112","article-title":"Breast cancer: Relationship between the size of the primary tumour and the probability of metastatic dissemination","volume":"49","author":"Koscielny","year":"1984","journal-title":"Br. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrc2627-c1","article-title":"Parallel progression of tumour and metastases","volume":"10","author":"Koscielny","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_20","first-page":"988","article-title":"Observations on growth rates of human tumors","volume":"76","author":"Collins","year":"1956","journal-title":"Am. J. Roentgenol. Radium Ther. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccr.2007.12.003","article-title":"Systemic spread is an early step in breast cancer","volume":"13","author":"Husemann","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1126\/science.1161621","article-title":"Seeding and propagation of untransformed mouse mammary cells in the lung","volume":"321","author":"Podsypanina","year":"2008","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1073\/pnas.1331931100","article-title":"From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression","volume":"100","author":"Ragg","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.15403\/jgld.2014.1121.261.haz","article-title":"How to Diagnose and Treat a Cancer of Unknown Primary Site","volume":"26","author":"Tomuleasa","year":"2017","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10555-006-9036-9","article-title":"Bone marrow cells in the \u2018pre-metastatic niche\u2019: Within bone and beyond","volume":"25","author":"Kaplan","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/cncr.21778","article-title":"Metastatic patterns in adenocarcinoma","volume":"106","author":"Hess","year":"2006","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrc2621","article-title":"The metastatic niche: Adapting the foreign soil","volume":"9","author":"Psaila","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nrc2622","article-title":"Metastasis: From dissemination to organ-specific colonization","volume":"9","author":"Nguyen","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrc1098","article-title":"The pathogenesis of cancer metastasis: The \u2018seed and soil\u2019 hypothesis revisited","volume":"3","author":"Fidler","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1101\/sqb.2005.70.018","article-title":"Identifying site-specific metastasis genes and functions","volume":"70","author":"Gupta","year":"2005","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.ejca.2010.02.026","article-title":"Interleukin-6 in bone metastasis and cancer progression","volume":"46","author":"Ara","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ewing, J. (1928). Neoplastic Diseases: A Treatise on Tumors, WB Saunders. [3rd ed.].","DOI":"10.1097\/00000441-192808000-00014"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1056\/NEJMra0805239","article-title":"Molecular basis of metastasis","volume":"359","author":"Chiang","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jcmgh.2017.01.006","article-title":"Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions","volume":"3","author":"Zarour","year":"2017","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1158\/1078-0432.CCR-07-4843","article-title":"The interleukin-8 pathway in cancer","volume":"14","author":"Waugh","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_36","first-page":"1","article-title":"Molecular Mechanisms of Bone Metastasis","volume":"13","author":"Weidle","year":"2016","journal-title":"Cancer Genom. Proteom."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7766","DOI":"10.1158\/0008-5472.CAN-05-3897","article-title":"Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation","volume":"66","author":"Goerge","year":"2006","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1186\/1755-1536-5-S1-S8","article-title":"Connective tissue growth factor in tumor pathogenesis","volume":"5","author":"Jacobson","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0304-3835(01)00524-9","article-title":"Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases","volume":"169","author":"Sotiriou","year":"2001","journal-title":"Cancer Lett."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1158\/1541-7786.MCR-07-0119","article-title":"Osteoactivin promotes breast cancer metastasis to bone","volume":"5","author":"Rose","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1538-7836.2011.04571.x","article-title":"Megakaryocytes, malignancy and bone marrow vascular niches","volume":"10","author":"Psaila","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_42","first-page":"18","article-title":"Cancer and bone","volume":"19","author":"Guise","year":"1998","journal-title":"Endocr. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.beem.2008.01.011","article-title":"Mechanisms of bone metastasis in prostate cancer: Clinical implications","volume":"22","author":"Msaouel","year":"2008","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/bonekey.2012.96","article-title":"The role of TGF-beta in bone metastasis: Novel therapeutic perspectives","volume":"1","author":"Buijs","year":"2012","journal-title":"Bonekey Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bone.2010.08.004","article-title":"TGF-beta in cancer and bone: Implications for treatment of bone metastases","volume":"48","author":"Juarez","year":"2011","journal-title":"Bone"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0303-7207(93)90074-T","article-title":"Transforming growth factor beta stimulation of parathyroid hormone-related protein (PTHrP): A paracrine regulator?","volume":"92","author":"Kiriyama","year":"1993","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/1535-7163.MCT-07-0234","article-title":"Molecular biology of bone metastasis","volume":"6","author":"Kingsley","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"24171","DOI":"10.1074\/jbc.M604507200","article-title":"Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression","volume":"281","author":"McMahon","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.semcancer.2012.04.002","article-title":"Induction of epithelial-mesenchymal transition by transforming growth factor beta","volume":"22","author":"Moustakas","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nri2808","article-title":"The polarization of immune cells in the tumour environment by TGFbeta","volume":"10","author":"Flavell","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.bone.2010.07.009","article-title":"Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain","volume":"48","author":"Yoneda","year":"2011","journal-title":"Bone"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.4103\/0973-1482.122505","article-title":"The role of neural-related factors in the metastasis of the gastrointestinal cancer","volume":"9","author":"Xu","year":"2013","journal-title":"J. Cancer Res. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/j.suronc.2012.06.001","article-title":"Matrix metalloproteinases: Potential therapy to prevent the development of second malignancies after breast radiotherapy","volume":"21","author":"Lara","year":"2012","journal-title":"Surg. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1182\/blood-2014-04-568683","article-title":"Interaction of platelet-derived autotaxin with tumor integrin alphaVbeta3 controls metastasis of breast cancer cells to bone","volume":"124","author":"Leblanc","year":"2014","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbalip.2012.06.004","article-title":"Pleiotropic activity of lysophosphatidic acid in bone metastasis","volume":"1831","author":"Peyruchaud","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: A fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1073\/pnas.0437939100","article-title":"IL-1 is required for tumor invasiveness and angiogenesis","volume":"100","author":"Voronov","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"201","DOI":"10.5173\/ceju.2011.04.art2","article-title":"Reciprocal cross-talk between Prostaglandin E2 and bone in prostate cancer: A current review","volume":"64","author":"Castellan","year":"2011","journal-title":"Cent. Eur. J. Urol."},{"key":"ref_60","first-page":"1647","article-title":"GM-CSF secreted by murine adenocarcinoma cells modulates tumor progression and immune activity","volume":"10","author":"Diament","year":"2003","journal-title":"Oncol. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000368414","article-title":"Anti-tumor necrosis factor therapy inhibits lung metastasis in an osteosarcoma cell line","volume":"88","author":"Kato","year":"2015","journal-title":"Oncology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semcancer.2015.08.010","article-title":"Complexity of cancer protease biology: Cathepsin K expression and function in cancer progression","volume":"35","author":"Verbovsek","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.critrevonc.2013.08.013","article-title":"Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers","volume":"89","author":"Kruger","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cytogfr.2015.11.009","article-title":"Mechanisms of action of bone morphogenetic proteins in cancer","volume":"27","author":"Davis","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5732\/cjc.012.10218","article-title":"Skeletal metastasis: Treatments, mouse models, and the Wnt signaling","volume":"32","author":"Valkenburg","year":"2013","journal-title":"Chin. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.2174\/138161210793563536","article-title":"Targeted therapy options for treatment of bone metastases; beyond bisphosphonates","volume":"16","author":"Buijs","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00262-011-1119-y","article-title":"The small molecule TGF-beta signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis","volume":"61","author":"Garrison","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ymeth.2011.07.001","article-title":"Internal radiotherapy of painful bone metastases","volume":"55","author":"Liepe","year":"2011","journal-title":"Methods"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.crad.2017.02.019","article-title":"Expanding role of percutaneous ablative and consolidative treatments for musculoskeletal tumours","volume":"72","author":"Kurup","year":"2017","journal-title":"Clin. Radiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1302\/2058-5241.2.170006","article-title":"Diagnostic algorithm, prognostic factors and surgical treatment of metastatic cancer diseases of the long bones and spine","volume":"2","author":"Szendroi","year":"2017","journal-title":"EFORT Open Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.canrad.2012.04.005","article-title":"Improvements of ablative local treatments modify the management of the oligometastatic disease","volume":"16","author":"Thariat","year":"2012","journal-title":"Cancer Radiother."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Kougioumtzopoulou, A., Zygogianni, A., Liakouli, Z., Kypraiou, E., and Kouloulias, V. (2017). The role of radiotherapy in bone metastases: A critical review of current literature. Eur. J. Cancer Care, 26.","DOI":"10.1111\/ecc.12724"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Chiras, J., Shotar, E., Cormier, E., and Clarencon, F. (2017). Interventional radiology in bone metastases. Eur. J. Cancer Care, 26.","DOI":"10.1111\/ecc.12741"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Laredo, J.D., Chiras, J., Kemel, S., Taihi, L., and Hamze, B. (2017). Vertebroplasty and interventional radiology procedures for bone metastases. Jt. Bone Spine.","DOI":"10.1016\/j.jbspin.2017.05.005"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jocn.2014.06.006","article-title":"Potential neurotoxic effects of polymethylmethacrylate during cranioplasty","volume":"22","author":"Pikis","year":"2015","journal-title":"J. Clin. Neurosci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.suronc.2013.02.008","article-title":"Insight opinion to surgically treated metastatic bone disease: Scandinavian Sarcoma Group Skeletal Metastasis Registry report of 1195 operated skeletal metastasis","volume":"22","author":"Ratasvuori","year":"2013","journal-title":"Surg. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.abb.2014.07.013","article-title":"Cancer and bone: A complex complex","volume":"561","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: Causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ctrv.2008.03.012","article-title":"Molecular treatment strategies and surgical reconstruction for metastatic bone diseases","volume":"34","author":"Zou","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.drudis.2013.08.010","article-title":"Is bisphosphonate therapy compromised by the emergence of adverse bone disorders?","volume":"19","author":"Verron","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.imlet.2012.04.014","article-title":"Chemokines and NK cells: Regulators of development, trafficking and functions","volume":"145","author":"Bernardini","year":"2012","journal-title":"Immunol. Lett."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nrclinonc.2013.169","article-title":"Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates","volume":"10","author":"Gronich","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Odri, G., Kim, P.P., Lamoureux, F., Charrier, C., Battaglia, S., Amiaud, J., Heymann, D., Gouin, F., and Redini, F. (2014). Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing\u2019s sarcoma via inhibition of cell migration. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-169"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-05-0264","article-title":"Bisphosphonates and cancer-induced bone disease: Beyond their antiresorptive activity","volume":"65","author":"Clezardin","year":"2005","journal-title":"Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ctrv.2008.03.006","article-title":"Antitumor effects of bisphosphonates: Promising preclinical evidence","volume":"34","author":"Guise","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/bonekey.2013.1","article-title":"Mechanisms of action of bisphosphonates in oncology: A scientific concept evolving from antiresorptive to anticancer activities","volume":"2","author":"Clezardin","year":"2013","journal-title":"Bonekey Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"6249","DOI":"10.1158\/1078-0432.CCR-12-0918","article-title":"In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vgamma9Vdelta2 T-cell antitumor cytotoxicity through ICAM-1 engagement","volume":"18","author":"Benzaid","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-10-3862","article-title":"High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo","volume":"71","author":"Benzaid","year":"2011","journal-title":"Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10522-011-9344-5","article-title":"Physiology of the aging bone and mechanisms of action of bisphosphonates","volume":"12","author":"Dominguez","year":"2011","journal-title":"Biogerontology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3816\/CLC.2004.n.030","article-title":"Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: Analysis based on history of skeletal complications","volume":"6","author":"Hirsh","year":"2004","journal-title":"Clin. Lung Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/bonekey.2015.113","article-title":"Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma","volume":"4","author":"Terpos","year":"2015","journal-title":"Bonekey Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JOP.2011.000212","article-title":"American society of clinical oncology clinical practice guideline update: Recommendations on the role of bone-modifying agents in metastatic breast cancer","volume":"7","author":"Temin","year":"2011","journal-title":"J. Oncol. Pract."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/jnci\/djs263","article-title":"Effects of bone-targeted agents on cancer progression and mortality","volume":"104","author":"Coleman","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bone.2014.08.018","article-title":"Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies","volume":"68","author":"Lezot","year":"2014","journal-title":"Bone"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1517\/13543784.17.11.1703","article-title":"Novel bone cancer drugs: Investigational agents and control paradigms for primary bone sarcomas (Ewing\u2019s sarcoma and osteosarcoma)","volume":"17","author":"Anderson","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/1758834014521110","article-title":"Bone and brain metastasis in lung cancer: Recent advances in therapeutic strategies","volume":"6","author":"Passaro","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3747\/co.19.1011","article-title":"Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: The state of the art","volume":"19","author":"Clemons","year":"2012","journal-title":"Curr. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ctrv.2012.07.002","article-title":"Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysis","volume":"39","author":"Peddi","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mce.2009.07.004","article-title":"The critical role of the bone microenvironment in cancer metastases","volume":"310","author":"Casimiro","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/cancers5020591","article-title":"Current therapeutic strategies and novel approaches in osteosarcoma","volume":"5","author":"Ando","year":"2013","journal-title":"Cancers"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.canlet.2009.01.011","article-title":"Mechanism of bone metastasis: The role of osteoprotegerin and of the host-tissue microenvironment-related survival factors","volume":"283","author":"Fili","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_106","first-page":"49","article-title":"RANKL\/RANK\/OPG: New therapeutic targets in bone tumours and associated osteolysis","volume":"1704","author":"Wittrant","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.bcp.2011.12.015","article-title":"Molecular effects of gallium on osteoclastic differentiation of mouse and human monocytes","volume":"83","author":"Verron","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Strazic Geljic, I., Melis, N., Boukhechba, F., Schaub, S., Mellier, C., Janvier, P., Laugier, J.P., Bouler, J.M., Verron, E., and Scimeca, J.C. (2017). Gallium enhances reconstructive properties of a calcium phosphate bone biomaterial. J. Tissue Eng. Regen. Med.","DOI":"10.1002\/term.2396"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bcp.2016.06.020","article-title":"Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases","volume":"116","author":"Guberovic","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.drudis.2017.04.007","article-title":"The multiple therapeutic applications of miRNAs for bone regenerative medicine","volume":"22","author":"Scimeca","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"L27","DOI":"10.1530\/ERC-16-0487","article-title":"miR-16 is highly expressed in Paget\u2019s associated osteosarcoma","volume":"24","author":"Green","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/ejhg.2010.209","article-title":"Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome","volume":"19","author":"Krejcik","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/aja.2012.116","article-title":"An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions","volume":"15","author":"Zhang","year":"2013","journal-title":"Asian J. Androl."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature13375","article-title":"miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2","volume":"512","author":"Krzeszinski","year":"2014","journal-title":"Nature"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","article-title":"Targeting TGF-beta Signaling in Cancer","volume":"3","author":"Colak","year":"2017","journal-title":"Trends Cancer"},{"key":"ref_116","first-page":"4479","article-title":"Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"9","author":"Herbertz","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-1-4419-9129-4_9","article-title":"Endothelins in bone cancer metastases","volume":"118","author":"Guise","year":"2004","journal-title":"Cancer Treat. Res."},{"key":"ref_118","first-page":"3465","article-title":"Endothelin-A receptor antagonists in prostate cancer treatment-a meta-analysis","volume":"8","author":"Qiao","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s00277-015-2442-8","article-title":"VLA-4 and CXCR4 expression levels show contrasting prognostic impact (favorable and unfavorable, respectively) in acute myeloid leukemia","volume":"94","author":"Bae","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/0008-5472.967.65.3","article-title":"Silencing of CXCR4 blocks breast cancer metastasis","volume":"65","author":"Liang","year":"2005","journal-title":"Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/carcin\/bgm050","article-title":"The role of PTEN in prostate cancer cell tropism to the bone micro-environment","volume":"28","author":"Wu","year":"2007","journal-title":"Carcinogenesis"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"45826","DOI":"10.1074\/jbc.M309024200","article-title":"Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity","volume":"278","author":"Peyruchaud","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.tips.2015.04.006","article-title":"New therapeutic targets for cancer bone metastasis","volume":"36","author":"Krzeszinski","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.biopha.2017.09.025","article-title":"MTA1 expression in human cancers\u2014Clinical and pharmacological significance","volume":"95","author":"Malisetty","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neulet.2013.08.003","article-title":"Cancer-induced bone pain: Mechanisms and models","volume":"557","author":"Vanderah","year":"2013","journal-title":"Neurosci. Lett."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/74999","article-title":"Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord","volume":"6","author":"Honore","year":"2000","journal-title":"Nat. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"945","DOI":"10.12688\/f1000research.10817.1","article-title":"Recent advances in understanding and managing cancer pain","volume":"6","author":"Chwistek","year":"2017","journal-title":"F1000Research"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Itatani, Y., Kawada, K., Inamoto, S., Yamamoto, T., Ogawa, R., Taketo, M.M., and Sakai, Y. (2016). The Role of Chemokines in Promoting Colorectal Cancer Invasion\/Metastasis. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17050643"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1042\/BJ20071493","article-title":"Chemokines and cancer: Migration, intracellular signalling and intercellular communication in the microenvironment","volume":"409","author":"Salanga","year":"2008","journal-title":"Biochem. J."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.ejca.2006.01.002","article-title":"Inflammatory chemokines in cancer growth and progression","volume":"42","author":"Rollins","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.18632\/oncotarget.1426","article-title":"Chemokines in tumor progression and metastasis","volume":"4","author":"Sarvaiya","year":"2013","journal-title":"Oncotarget"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1359-6101(01)00033-8","article-title":"Chemokines in cancer","volume":"13","author":"Vicari","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"768758","DOI":"10.1155\/2014\/768758","article-title":"CXC and CC chemokines as angiogenic modulators in nonhaematological tumors","volume":"2014","author":"Santoni","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fonc.2014.00069","article-title":"The impact of the immune system on tumor: Angiogenesis and vascular remodeling","volume":"4","author":"Stockmann","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40495-015-0044-8","article-title":"Potential of CXCR4\/CXCL12 Chemokine Axis in Cancer Drug Delivery","volume":"2","author":"Wang","year":"2016","journal-title":"Curr. Pharmacol. Rep."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2005.11.002","article-title":"Regulatory T cells: How do they find their space in the immunological arena?","volume":"16","year":"2006","journal-title":"Semin. Cancer Biol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1158\/0008-5472.CAN-12-2027","article-title":"Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response","volume":"72","author":"Franciszkiewicz","year":"2012","journal-title":"Cancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.imlet.2012.11.002","article-title":"Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells","volume":"149","author":"Hemdan","year":"2013","journal-title":"Immunol. Lett."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0167-5699(98)01346-2","article-title":"Chemokines and chemokine receptors in T-cell priming and Th1\/Th2-mediated responses","volume":"19","author":"Sallusto","year":"1998","journal-title":"Immunol. Today"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.it.2012.05.007","article-title":"The pros and cons of chemokines in tumor immunology","volume":"33","author":"Viola","year":"2012","journal-title":"Trends Immunol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc1252","article-title":"Cytokines in cancer pathogenesis and cancer therapy","volume":"4","author":"Dranoff","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cytogfr.2009.11.007","article-title":"The chemokine system in cancer biology and therapy","volume":"21","author":"Mantovani","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/nm.2830","article-title":"Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape","volume":"18","author":"Bidwell","year":"2012","journal-title":"Nat. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/1\/148\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:50:06Z","timestamp":1760194206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/1\/148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,4]]},"references-count":143,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1]]}},"alternative-id":["ijms19010148"],"URL":"https:\/\/doi.org\/10.3390\/ijms19010148","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,4]]}}}